Form 13-F position report

TITAN PHARMACEUTICALS INC D

Reported by MORGAN STANLEY

TTNP CUSIP 888314705 Manager CIK 0000895421

Reported 2 shares, down 2 (50.0%) from the prior quarter.

Reported value -46.7%; share count -50.0% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 2 Quarter-end amount reported
Reported value $8 Fair value at quarter end
Consecutive quarters held 39 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 0
2022-03-31 0
2022-06-30 0
2022-09-30 0
2022-12-31 22
2023-03-31 23
2023-06-30 10
2023-09-30 8
2023-12-31 0
2024-03-31 21
2024-06-30 17
2024-09-30 21
2024-12-31 10
2025-03-31 15
2025-06-30 8
2025-09-30 10
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for TITAN PHARMACEUTICALS INC D held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -2 (-100.0%) 0 $0 2026-02-13
Q3 2025 Unchanged 2 0 (0.0%) < 0.01% $10 2025-11-14
Q2 2025 Reduced 2 -2 (-50.0%) < 0.01% $8 2025-08-15
Q1 2025 Added 4 +1 (33.3%) < 0.01% $15 2025-05-15
Q4 2024 Reduced 3 -1 (-25.0%) < 0.01% $10 2025-02-14
Q3 2024 Added 4 +1 (33.3%) < 0.01% $21 2024-11-14
Q2 2024 Unchanged 3 0 (0.0%) < 0.01% $17 2024-08-14
Q1 2024 New 3 +3 (0.0%) < 0.01% $21 2024-05-15
Q4 2023 Reduced 0 -16 (-100.0%) 0 $0 2024-02-13
Q3 2023 Unchanged 16 0 (0.0%) < 0.01% $8 2023-11-15
Q2 2023 Reduced 16 -12 (-42.9%) < 0.01% $10 2023-08-14
Q1 2023 Unchanged 28 0 (0.0%) < 0.01% $23 2023-05-15
Q4 2022 Reduced 28 -12 (-30.0%) < 0.01% $22 2023-02-14
Q3 2022 Added 40 +24 (150.0%) 0 $0 2022-11-14
Q2 2022 Unchanged 16 0 (0.0%) 0 $0 2022-08-15
Q1 2022 Unchanged 16 0 (0.0%) 0 $0 2022-05-13
Q4 2021 Reduced 16 -90,467 (-100.0%) 0 $0 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

21 managers reported TITAN PHARMACEUTICALS INC D for Q2 2025.

Managers reporting TITAN PHARMACEUTICALS INC D in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
CITADEL ADVISORS LLC Added 12,069 +108 < 0.01% $50,690 2 qtrs
RENAISSANCE TECHNOLOGIES LLC New 11,380 +11,380 < 0.01% $47,796 1 qtr
Marex Group plc New 10,663 +10,663 < 0.01% $44,785 1 qtr
UBS Group AG Added 3,427 +833 < 0.01% $14,393 6 qtrs
CoreCap Advisors LLC Unchanged 88 0 < 0.01% $370 2 qtrs
Bank of America Corporation Unchanged 18 0 < 0.01% $75 6 qtrs
GROUP ONE TRADING L P Unchanged 12 0 < 0.01% $50 6 qtrs
ADVISOR GROUP HOLDINGS INC Reduced 10 -5 < 0.01% $40 6 qtrs
BlackRock Inc Unchanged 6 0 < 0.01% $25 2 qtrs
MORGAN STANLEY This report Reduced 2 -2 < 0.01% $8 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 15, 2025
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
1
Shared
0
None
1

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.